Oncology Central

PERSIST-1: Phase III study of pacritinib versus best available therapy in patients with myelofibrosis

0

In this short video, expert Ruben Mesa of Mayo Clinic (AZ, USA) gives an overview of the results of the Phase III PERSIST-1 trial, which were presented at the 2015 Annual Meeting of the American Society for Clinical Oncology.

The trial investigated the use of the JAK2/FLT3 inhibitor pacritinib in patients with myelofibrosis. Having demonstrated promising results in Phase II, Phase III PERSIST-1 demonstrated that the agent was safe and efficacious, suggesting overall that pacritinib will be an important option for patient with myelofibrosis.

Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.